New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
16:25 EDTLRN, LGND, LOW, DMND, TSN, GSK, INTCOn The Fly: Closing Wrap
Stocks on Wall Street were higher after the averages all advanced sharply at the open and maintained gains through the trading day. Optimism about hopes for a resolution to the fiscal cliff helped push stocks into positive territory Friday and that positive momentum carried over as the new week began. Positive economic data from the National Association of Realtors also buoyed investor confidence on the day... ECONOMIC EVENTS: In the U.S., the National Association of Realtors said that resales of existing homes climbed 2.1% last month to a seasonally adjusted annual rate of 4.79M units, beating forecasts for sales to have declined 0.2% from the prior month. The housing market index for November, a barometer of homebuilder sentiment, rose to 46, versus expectations for a flat 41 reading... COMPANY NEWS: Lowe's (LOW) reported earnings per share with charges that met expectations and revenue that beat consensus, sending shares higher $1.98, or 6.19%, to $33.96... Intel's (INTC) CEO Paul Otellini announced plans to retire in May and shares leveled off after some early day volatility, ending up 6c, or 0.30%, to $20.25... MAJOR MOVERS: Among the notable gainers was Tyson Foods (TSN), advancing $1.84, or 10.90%, to $18.72 after its quarterly earnings beat consensus and the company raised its regular dividend and declared a special dividend. Also higher were shares of Ligan Pharmaceuticals (LGND), up $2.40, or 14.40%, to $19.07 after the company's partner GlaxoSmithKline (GSK) said the FDA approved a new indication for its supportive care treatment for a condition associated with chronic hepatitis C. Among noteworthy losers was (DMND), down $1.79 or 11.83%, to $13.34 after the stock was downgraded to Underperform from Hold at Jeffries. Also lower were shares of K12 (LRN), down $3.84, or 18.78%, to $16.61 following a downgrade to Market Perform at Wells Fargo prompted by issues at one of its schools in Colorado. The company said in a midday release that it has been working "for some time" with Colorado Virtual Academy to address the performance issues that have arisen there... INDICES: The Dow was up 207.65, or 1.65%, to 12,795.96; the Nasdaq was up 62.94, or 2.21%, to 2,916.07; and the S&P 500 was up 27.01, or 1.99%, to 1,386.89.
News For LOW;INTC;TSN;LGND;GSK;DMND;LRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 27, 2015
10:47 EDTINTCQualcomm rises in down market after Morgan Stanley upgrade
Subscribe for More Information
10:35 EDTINTCIntel, Micron gain after announcing joint press event
Subscribe for More Information
09:36 EDTINTCActive equity options trading on open
Active equity options trading on open: AAPL NFLX INTC MU VZ BIDU AMBA
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
06:36 EDTINTCIntel to adopt Skylake CPUs in NUC and Computer Stick, DigiTimes reports
Subscribe for More Information
July 24, 2015
12:44 EDTLGNDAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTLGNDFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
09:02 EDTLGNDLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
06:13 EDTINTCAnalysts say Intel best suitor for Qualcomm's chip unit, Reuters says
Subscribe for More Information
05:04 EDTGSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
19:24 EDTLOWWal-Mart's Apple Pay competitor launching soon, Bloomberg says
CurrentC, the mobile payment application funded by Wal-Mart (WMT), Target (TGT), Best Buy (BBY) and others, will see an early trial run next month, Bloomberg reported earlier, citing three people familiar with the situation. A spokesperson for Lowe's (LOW) said the consortium behind the app expects an official launch in Q3, and Bloomberg noted that CurrentC will compete with more "established" offerings such as Apple's (AAPL) Apple Pay and Google's (GOOG) Android Pay. Reference Link
12:04 EDTINTCRackspace, Intel announce OpenStack collaboration
Subscribe for More Information
06:22 EDTINTCIntel to release notebook Skylake processor in October, DigiTimes reports
Intel is expected to release its upcoming notebook Skylake processor in October, reports DigiTimes. The company is planning to launch a total of 18 notebook Skylake processors in Q4 as it looks to help boost notebook demand. The company is adjusting their schedules for Skylake products to minimize the impact of inventory issues. Reference Link
July 22, 2015
14:51 EDTINTCEarnings Watch: Qualcomm reports after speculations of potential breakup
Qualcomm (QCOM) is expected to report third quarter earnings after the close on July 22, with a conference call scheduled for 4:45 pm ET. Qualcomm is a maker of semiconductors and telecommunications equipment. EXPECTATIONS: Analysts are looking for earnings per share of 95c on revenue of $5.85B. EPS consensus ranges 90c-$1.05 on a revenue range of $5.59B-$6.08B, according to First Call. LAST QUARTER: On April 22, Qualcomm reported Q2 EPS of $1.40 against expectations for $1.33, and revenue of $6.89B versus estimates of $6.83B. The company also cut its FY15 EPS guidance to $4.60-$5.00 from $4.85-$5.05 and lowered projected revenue to $25B-$27B from $26.3B-$28B, saying it expects pressure in its semiconductor business due to customer shifts in the premium segment and a decline in Qualcomm's share at an unnamed large customer. NEWS: On May 8, Reuters reported that EU antitrust regulators asked Qualcomm's competitors how the company's licensing and business practices affect them, and on July 16, the European Commission confirmed two formal antitrust investigations of the company. On May 25, Qualcomm and Daimler (DDAIF) announced a strategic collaboration to develop connected car technology. Coming on the heels of Avago's (AVGO) May 28 agreement to acquire Broadcom (BRCM), Bloomberg quoted a source later that day as saying Qualcomm, Intel (INTC), Altera (ALTR), Analog Devices (ADI), Maxim Integrated (MXIM), Texas Instruments (TXN), and Microchip Technology (MCHP) are all considering their own M&A opportunities. Note that on June 1, Intel announced an agreement to acquire Altera. On June 23, Semiconductor Manufacturing International (SMI), Qualcomm, Huawei, and Imec announced the formation of a joint venture to focus on a type of 14 nanometer technology. More recently, the Wall Street Journal reported on July 20 that Qualcomm is "expected" to begin a comprehensive strategic review which may include the possibility of a breakup following pressure from "activist" shareholder Jana Partners, according to sources, adding that the move could be announced concurrent with Wednesday's earnings release. STREET RESEARCH: Following last quarter's earnings report, Exane BNP Paribas downgraded Qualcomm to Neutral from Outperform, while both Canaccord and Brean Capital lowered price targets for the stock after "disappointing" guidance. Meanwhile, Citi said it expects the company's chip business to recover in 2016 despite this "very bad year." On May 28, CLSA said it sees continued pressure on Qualcomm chipsets, potentially spurring the company to consider making an acquisition, and on June 2, Craig-Hallum noted that Skyworks (SWKS) would be a great fit for Qualcomm. On June 24, Summit Research called Applied Micro Circuits (AMCC) an "affordable" target for Qualcomm, with AMD (AMD) and Cavium (CAVM) also looking like potential takeover candidates. On June 29, Drexel Hamilton downgraded Qualcomm to Sell from Hold, citing expected price cuts. Lastly, following media reports on July 20 that Qualcomm could be weighing a breakup, Bernstein said that such a "dis-synergistic" split would likely destroy value rather than create it. PRICE ACTION: Shares of Qualcomm are down more than 1% to $64.37 in afternoon trading ahead of Wednesday's earnings report.
14:37 EDTLOWHome improvement stocks rally after Owens Corning results, home sales data
Subscribe for More Information
06:15 EDTINTCGoogle's updated Glass to be foldable, more weather-resistant, 9to5Google says
Subscribe for More Information
July 20, 2015
09:34 EDTINTCActive equity options trading on open
Subscribe for More Information
06:49 EDTLOWDeutsche goes below consensus on Home Depot, Lowe's
Subscribe for More Information
July 19, 2015
15:54 EDTINTCTSMC confirms 10nm mass production in 1Q17, DigiTimes says
Subscribe for More Information
14:09 EDTINTCIntel chip delay could spell opportunity or disaster, Barron's says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use